Get in touch today to find out more about our individualized weight management treatment programs.

Related Posts


Triple G Agonists – Retatrutide. What is all the buzz? 

Written by Dr Girouard M.D.

Updated November 23, 2023

If you have had an ear to the ground on exciting new, “better than surgery” treatments for weight loss then you would have heard about the new hormone-based therapy called “Triple G”.   Studies released earlier this year are showing some incredible results with up to 24% weight loss in just 48 weeks!  WOW!! (this reminds me of this song… “Hot Hot Hot” from the 80’s! )

What are the “triple three” in “triple G”?  They are the G-protein-coupled receptors: 

      1. GLP-1(glucagon-like peptide-1) receptor 

      2. GIP (glucose-dependent insulinotropic polypeptide) receptor 

      3. Glucagon (GCG) receptor 

You’ve already heard some of these “G’s” in the weight loss world.  The first “G” was a GLP-1 receptor agonist approved for weight loss years ago called Saxenda (liraglutide) then came along Wegovy (semaglutide). In 2022, Mounjaro (tirzepatide), a new and novel combination GLP-1/GIP receptor agonist, became available as an FDA approved treatment for type 2 diabetes and should be approved soon for weight loss as studies have shown up to a 21% weight loss!  

“Triple G” has all three – so think of it as “Mounjaro plus”.  The “plus” is the GCG receptor.  Sometimes more really is better.  Having all three receptors has shown better weight loss results than just one or two receptors by themselves. 

“GCG is best recognized as a counterregulatory hormone released from pancreatic α cells during hypoglycemia, increasing blood glucose. However, GCG also has potent catabolic effects, in that it stimulates adipose lipolysis, reduces food intake, slows gastric emptying, and increases energy expenditure. Thus, incorporating GCG receptor agonism may further enhance weight loss, while simultaneous incretin-mimetic action of GLP-1–GIP signalling can balance the potential adverse glycemic effects of GCG. Preclinical studies showed that triple G agonists were superior to single or dual agonists for achieving weight loss, reducing hepatic steatosis, and normalizing glucose levels.” (direct from first blog in source.) 


What does that all mean?

In means that “Triple G” doesn’t just work in “triple” ways, it works in a LOT of ways to help a person lose unwanted excess body weight.  It does so by hitting all 3 receptors that together do the following: 

    • Decreasing a person’s appetite and drive to eat. 
    • Decreases how quickly a person’s stomach empties, helping them feel full quicker and for longer. 
    • Decreases the size of meal portions (see above reason). 
    • Increases a person’s metabolic rate so they burn more calories without exercising more! 
    • Helps fat get out of the fat cells so it can be burned for energy and not stored for a “rainy day”. 
    • Helps regulate a person’s blood sugar levels. 
    • Improves insulin resistance and reduces high insulin levels (high insulin levels increase a person’s risk of other health problems – high blood pressure, heart disease, cancer…) 

“Triple G” (Retatrutide) is not yet available for our patients.  It is still in clinical trials and then it will need to be FDA approved before it is available.  We are continuing to follow the research and we look forward to sharing with you when it is available. 

“We are excited to see so many new and effective options and combinations of options become available for our patients.”   

“Triple G” looks like it will be very, very promising and it is something we believe will be a great tool for our patients here at Dr. Girouard’s Clinics.   


  1. Triple G Agonists — A Home Run for Obesity? | NEJM 
  2. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial | NEJM 
  3. Tirzepatide – SURMOUNT 1 results: